| Basics |
Prothena Corporation plc Ordinary Shares
Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.
|
| IPO Date: |
December 21, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$595.9M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.87 | 2.88%
|
| Avg Daily Range (30 D): |
$0.23 | 2.23%
|
| Avg Daily Range (90 D): |
$0.19 | 2.06%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.38M |
| Avg Daily Volume (30 D): |
.49M |
| Avg Daily Volume (90 D): |
.69M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
60 |
| Avg Trade Size (Sh.) (90 D): |
71 |
| Institutional Trades |
| Total Inst.Trades: |
3,481 |
| Avg Inst. Trade: |
$1.86M |
| Avg Inst. Trade (30 D): |
$.76M |
| Avg Inst. Trade (90 D): |
$.9M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.19M |
| Avg Closing Trade (30 D): |
$.77M |
| Avg Closing Trade (90 D): |
$.86M |
| Avg Closing Volume: |
68.93K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-5.2
|
$-.68
|
$-2.34
|
|
Diluted EPS
|
$-5.2
|
$-.68
|
$-2.34
|
|
Revenue
|
$ 11.79M
|
$ 2.42M
|
$ 4.42M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -280.46M
|
$ -36.54M
|
$ -125.77M
|
|
Operating Income / Loss
|
$ -255.33M
|
$ -40.24M
|
$ -84.62M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -188.42M
|
$ -40.59M
|
$ -46.5M
|
|
PE Ratio
|
|
|
|
|
|
|
